Incretin hormone mimetics and analogues in diabetes therapeutics

被引：83

作者：

Green, Brian D. ^{[1
]}

Flatt, Peter R. ^{[2
]}

机构：

[1] Queens Univ Belfast, Sch Biol Sci, Belfast BT6 0NJ, Antrim, North Ireland

[2] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2007年 / 21卷 / 04期

关键词：

incretin; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; insulin; type-2; diabetes; glucose homeostasis; exendin;

D O I：

10.1016/j.beem.2007.09.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

引用

页码：497 / 516

页数：20

共 107 条

[1]

Aaboe K, 2007, DIABETOLOGIA, V50, pS248

[2] Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice [J].

Ahrén, B ;

Thomaseth, K ;

Pacini, G .

DIABETOLOGIA, 2005, 48 (10) :2140-2146

[3] ORAL GLUCOSE AUGMENTATION OF INSULIN-SECRETION - INTERACTIONS OF GASTRIC INHIBITORY POLYPEPTIDE WITH AMBIENT GLUCOSE AND INSULIN LEVELS [J].

ANDERSEN, DK ;

ELAHI, D ;

BROWN, JC ;

TOBIN, JD ;

ANDRES, R .

JOURNAL OF CLINICAL INVESTIGATION, 1978, 62 (01) :152-161

[4]

[Anonymous], CAN J PHYSL PHARM

[5] Biology of incretins: GLP-1 and GIP [J].

Baggio, Laurie L. ;

Drucker, Daniel J. .

GASTROENTEROLOGY, 2007, 132 (06) :2131-2157

[6] A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis [J].

Baggio, LL ;

Huang, QL ;

Brown, TJ ;

Drucker, DJ .

DIABETES, 2004, 53 (09) :2492-2500

[7] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [J].

Buse, JB ;

Henry, RR ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2004, 27 (11) :2628-2635

[8] Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor [J].

Buteau, J ;

Foisy, S ;

Joly, E ;

Prentki, M .

DIABETES, 2003, 52 (01) :124-132

[9] Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats [J].

Chelikani, PK ;

Haver, AC ;

Reidelberger, RD .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2005, 288 (06) :R1695-R1706

[10] A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice [J].

Chen, Desu ;

Liao, Jiayu ;

Li, Na ;

Zhou, Caihong ;

Liu, Qing ;

Wang, Guangxing ;

Zhang, Rui ;

Zhang, Song ;

Lin, Lilin ;

Chen, Kaixian ;

Xie, Xin ;

Nan, Fajun ;

Young, Andrew A. ;

Wang, Ming-Wei .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (03) :943-948

← 1 2 3 4 5 6 7 8 9 10 →